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Abstract
Background: Intravenous immunoglobulin (IVIg) treatment results in an effective response from patients with
acute-phase Kawasaki disease (KD), but 16.5% of them remain nonresponsive to IVIg. To address this therapeutic
challenge, we tried a new therapeutic drug, mizoribine (MZR), in a mouse model of KD, which we have established
using injections of Candida albicans water-soluble fractions (CAWS).
Methods: CAWS (4 mg/mouse) were injected intraperitoneally into C57BL/6N mice for 5 consecutive days. MZR or
IgG was administered for 5 days. After 4 weeks, the mice were sacrificed and autopsied, the hearts were fixed in
10% neutral formalin, and plasma was taken to measure cytokines and chemokines using the Bio-Plex system.
The incidence of panvasculitis in the coronary arteries and aortic root was 100% in the control group. The
incidence of panvasculitis in the MZR group decreased to 50%. Moreover, the scope and severity of the
inflammation of those sites were significantly reduced in the MZR group as well as the IgG group. On the other
hand, increased cytokines and chemokines, such as IL-1a, TNF-a, KC, MIP-1a, GM-CSF, and IL-13, in the
nontreatment group were significantly suppressed by treatment with MZR, but the MCP-1 level increased. In
addition, IL-1a, TNF-a, IL-10, IL-13, and MIP-1a were suppressed by treatment in the IgG group.
Results: The incidence of panvasculitis in the coronary arteries and aortic root was 100% in the control group. The
incidence of panvasculitis in the MZR group decreased to 50%. Moreover, the scope and severity of the
inflammation of those sites were significantly reduced in the MZR group as well as the IgG group. On the other
hand, increased cytokines and chemokines, such as IL-1a TNF-a, KC, MIP-1a, GM-CSF, and IL-13, in the
nontreatment group were significantly suppressed by treatment with MZR, but the MCP-1 level increased. In
addition, IL-1a, TNF-a, IL-10, IL-13, and MIP-1a were suppressed by treatment in the IgG group.
Conclusion: MZR treatment suppressed not only the incidence, range, and degree of vasculitis, but also
inflammatory cytokines and chemokines in the plasma of the KD vasculitis model mice, suggesting that MZR may
be useful for treatment of KD.
Keywords: Kawasaki disease, an animal model, IVIg, coronary arteritis, inflammatory cytokines and chemokines,
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Kawasaki disease (KD) is an acute febrile illness that
manifests mainly in infancy and early childhood [1]. The
most important complication of KD is coronary arteritis,
which leads to formation of aneurysms. KD has
attracted special interest because it may cause ischemic
heart disease in children due to thrombosed coronary
aneurysms [2]. Since the etiology and development of
KD are thought to be due to the dysfunction of the
immune system, intravenous immunoglobulin (IVIg)
during the early acute phase has been used with an
excellent response in most patients [3]. However, 16.5%
of patients did not respond to the first IVIg treatment
[4], and some nonresponders to the first IVIg treatment
manifested severe coronary arteritis with large aneurysm
[5]. Therefore, additional treatments have been tried on
the nonresponders to the first treatment with IVIg. To
date, a second IVIg treatment [6], plasmapheresis [7-10],
pulse steroids [11], cyclophosphamide plus steroids [12],
ulinastatin as an elastase inhibitor [13-16], cyclosporin
A plus steroids and methotrexate plus steroids [17,18],
and anti-tumor necrosis factor-a (infliximab) therapy
[19-23] have been tried. Thus, for treatment of patients
w i t hK Dw h od on o tr e s p o n dt oI V I g ,o t h e rm e d i c i n e s
for immune response and suppression of lymphocyte
proliferation have been applied due to immune dysfunc-
tion in the patients. One immune modulating medicine,
mizoribine (MZR), a drug that inhibits synthesis of pur-
ine compounds (GMP), blocks proliferation of lympho-
cytes and will be useful for application to
nonresponders to IVIg treatment. MZR has long been
used as therapy for kidney transplantation, lupus nephri-
tis, nephrotic syndrome, and rheumatoid disease with
few side-effects [24]. Moreover, it has been reported to
have been used for lupus nephritis, nephrotic syndrome,
and IgA nephritis in children [25-28], and as a mainte-
nance therapy in anti-neutrophil cytoplasmic autoanti-
body (ANCA)-associated renal failure, frequently
relapsing nephrotic syndrome, and purpura nephritis
[29,30]. Therefore, MZR will be a valuable therapeutic
strategy for patients with KD who are nonresponsive to
IVIg.
Prior to a clinical trial in children with KD, it was
necessary to test MZR in a mouse model of KD, which
has been established. The model we chose was the
mouse model in which coronary arteritis can be induced
by administration of Candida albicans water-soluble
fractions (CAWS) [31]. This model mouse has pre-
viously been useful for evaluation of other drug
treatments.
Therefore, in the present study, we tested MZR as a
immunomodular for treatment of this CAWS-induced
coronary arteritis. The evaluation of MZR was
performed by histopathological findings and profiles of
chemokines and cytokines. Also, this treatment effect
was compared with that of IgG.
Methods
Animals
Four-week-old male C57BL/6N mice were purchased
from Charles River Japan (Yokohama, Japan). All mice
were kept under specific pathogen-free (SPF) conditions,
according to the guidelines for animal care of the
National Institute of Infectious Diseases in Tokyo
(NIID).
Preparation of CAWS
CAWS was prepared from C. albicans strain IFO1385 in
accordance with the reported method [31]. Briefly, 5
liters of medium (C-limiting medium) was added to a
glass incubator, and the culture was maintained for 2
days at 27°C while air was supplied at a rate of 5 liters/
min and the mixture was swirled at 400 rpm. Following
culture, an equal volume of ethanol was added. After
allowing this to stand overnight, the precipitate was col-
lected. After dissolving the precipitate in 250 ml of dis-
tilled water, ethanol was added and the mixture was
allowed to stand overnight. The precipitate was col-
lected and dried with acetone to obtain CAWS.
Administration of MZR and IgG to the mice
CAWS (4 mg/mouse/day) in a volume of 0.2 ml was
intraperitoneally injected into a C57BL/6N mouse (4-
week old male) on each of 5 consecutive days. Subse-
quently, MZR (a kind gift of Asahikasei Pharma Cor-
poration (Tokyo, Japan)) was administered at a dose of
30 mg/kg/day intraperitoneally for 5 days from the third
day of CAWS injection (MZB group), according to the
schecule for treatments such as IgG for patients with
KD, and the dosage as described elsewhere [32]. Mice
for the control group were intraperitoneally treated with
0 . 2m lo fD u l b e c c o ’s phosphate-buffered saline (PBS).
After 35 days, the mice were sacrificed by carbon diox-
ide asphyxiation; autopsy was performed to obtain
plasma, and hearts were fixed with 10% neutralized for-
malin. For a positive control, treatment with intraperito-
neal human IgG (Kenketsu Glovenin I, a kind gift of
Nihon Pharmaceutical Co. Ltd., Tokyo, Japan) was per-
formed at a dose of 400 mg/mouse/day, or for a nega-
tive control saline containing 0.1% glucose (SG) was
injected for 5 days according to the same procedures as
described elsewhere (IgG group) [33]. The start date of
the drug administration was based on the results that
the administration from the third experimental day had
been the most effective to suppress the development of
vasculitis.
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The fixed hearts were embedded in paraffin and sec-
tioned. To observe the histological changes in the cor-
onary arteries and the aorta in detail, 20 to 30
horizontal step sections per mouse were made every
20 μm. Hematoxylin and eosin (H&E)-stained sections
were prepared by using routine techniques for exami-
nation by light microscopy [31]. First, we investigated
the incidence of mice with panvasculitis in each group.
Panvasculitis was defined as inflammation of all layers
of the walls of the coronary arteries and/or the aorta.
Then, for quantitative evaluation of vascular inflamma-
tion, we divided the area of the aortic root and coron-
ary arteries into five segments and graded the intensity
of inflammation in each segment as follows: score 3,
panvasculitis; score 2, inflammation involving the
tunica intima and adventitia; score 1, inflammation
localized to the tunica intima; and score 0, no inflam-
matory cell infiltration in the vascular wall. A section
with the severe inflammation was observed in each
segment. The scope of inflammation was defined as
the number of segments evaluated as score 1 or more
in each mouse, and the severity of the arteritis was
defined as the average score of the five segments in
each mouse.
Measurement of cytokines and chemokines with Bio-Plex
Cytokines and chemokines in the plasma of mice autop-
sied were measured by a Bio-Plex system. An aliquot of
serum (12 μl) collected from peripheral blood and
diluted 4-fold with the dilution solution was measured
for concentration of cytokines by the 23-Plex kit using
Bio-Plex 200 according to the manufacturer’sp r o t o c o l
and analyzed by the Bio-Plex Luminex 100 XYP instru-
ment (Bio-Rad, Hercules, California, USA). We assayed
the following 23 cytokines and chemokines: IL-1a,I L -
1b, IL-2, IL-3, IL-4, IL-5, IL-6, IL-9, IL-10, IL-12p40, IL-
12p70, IL-13, IL-17, eotaxin, G-CSF, GM-CSF, INF-g,
KC, MCP-1, MIP-1a,M I P - 1 b,R A N T E S ,a n dT N F - a as
estimated with a single assay to a single standard curve
described in the kit instructions. Concentrations of cyto-
kines and chemokines were calculated using Bio-Plex
Manager 3.0 software (Bio-Rad, Tokyo) with a five-para-
meter curve-fitting algorithm applied for standard curve
calculations [34].
Statistical analysis
Fisher’s exact probability test was used to analyze the
differences in the incidence of arteritis among the
groups. The data on the scope and severity of the arteri-
tis and cytokine/chemokine levels were analyzed using
the two-sample t-test. A value of P < 0.05 was consid-
ered statistically significant.
Results
Histological evaluation of panvasculitis in treatment with
MZR
Panvasculitis developed in the coronary arteries and the
aortic root, and histology was similar to that previously
described [33]. Specifically, vascular changes were classi-
fied as proliferative inflammation that consisted mainly
of large mononuclear cells such as histiocytes and fibro-
blasts and of a small number of neutrophils. The normal
structure of the arteries was completely destroyed, and
the internal elastic lamina, external elastic lamina, and
smooth muscle layer of the tunica media were severely
damaged. However, fibrinoid necrosis was not observed
in any of the mice. In addition, the histology of panvas-
culitis was similar in the three groups (Figure 1).
Decrease of coronary arteritis by treatment with MZR
Panvasculitis of the coronary arteries and the aortic root
was observed in 5 of 5 mice (100%) in the nontreated
control group. On the other hand, the incidence of pan-
vasculitis in the MZR group was 3 of 6 mice (50%), and
the IgG group as an effective control showed 3 of 7
(43%) (Figure 2A). In addition, the number of segments
evaluated as score 1 or more in each MZR group was
decreased compared with the nontreated control group
(P = 0.06), and the scope of inflammation in IgG groups
was significantly lower than in the control group (P <
0.05) (Figure 2B). Furthermore, the severity of the arteri-
tis, i.e., the scores of each of five segments in the mice
in the MZR and IgG groups, was significantly lower
than in the nontreated control group (P < 0.01) (Figure
2C).
Reduction of inflammatory cytokines and chemokines by
treatment with MZR and IgG
Inflammatory cytokines IL-1a,T N F - a,c h e m o k i n e sK C ,
MIP-1a,G M - C S F ,a n dT h 2 ,a n dc y t o k i n eI L - 1 3i n
plasma of mice, which were inoculated with CAWS in
the control group, were elevated (Figure 3). However, in
the MZR group, plasma levels of inflammatory cytokines
IL-1a (P < 0.01) and TNF-a (P < 0.05), and chemokines
KC (P <0 . 0 1 ) ,M I P - 1 a (P <0 . 0 1 ) ,a n dG M - C S F( P <
0.05) were significantly suppressed (Figure 3A). Inver-
sely, the MCP-1 level increased with MZR treatment
(Figure 3A). On the other hand, IL-1a (P <0 . 0 5 ) ,T N F -
a (P < 0.05), IL-10 (P < 0.05), and IL-13 (P < 0.01) were
suppressed by administration of IgG (Figure 3B).
Furthermore, we analyzed levels of cytokines/chemo-
kines in plasma, which were related with suppression of
the development of coronary arteritis by treatment with
MZR. As shown in Figure 4A, the suppression levels
were almost the same in all plasmas of MZR-treated
mice. These results are not the same as those in the IgG
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Figure 1 Histological observations of coronary arteritis induced by treatment with MZR and IgG. A, Control (PBS); B, MZR group; C, IgG
group. Each micrograph represents an individual mouse. H&E stain, Bar: 500 μm. Numbers (white) are coronary arteritis score.
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Figure 2 Decrease of incidence of panvasculitis, segment score, and severity score of coronary arteritis by treatment with MZR and
IgG. A, incidence of development of panvasculitis; B, scope as number of segments with inflammation evaluated as score 1 or more at aortic
root and coronary arteries; C, severity score of each segment. Data are expressed as mean ± SD of results from three individuals. *P < 0.05 and
**P < 0.01 (Student’s t-test).
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Page 5 of 10group, showing good response for suppression of the
development of coronary arteritis (Figure 4B).
Discussion
Decrease of coronary arteritis by treatment with MZR
We here have shown the efficacy of MZR on vascular
inflammation by using a KD vasculitis mouse model to
develop alternative treatments for KD patients who are
nonresponsive to IVIg treatment. The results here show
that the incidence, scope, and degree of inflammation of
t h ec o r o n a r ya r t e r i e sa n dt h ea o r t i cr o o tw e r es u p -
pressed by MZR administration. Coronary arteritis in
this CAWS-induced vasculitis mouse model is also sup-
pressed after administration of IVIg [33]. Furthermore,
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Figure 3 Reduction and enhancement of cytokines and chemokines by treatment with MZR and IgG. A, MZR treatment; B, IgG treatment.
SG: saline including 0.1% glucose. Data are expressed as mean ± SD of results from three individuals. *P < 0.05 and **P < 0.01.
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Figure 4 Reduction and enhancement of cytokines and chemokines in coronary arteritis treated with MZR and IgG. A, MZR treatment;
B, IgG treatment. CA(+): coronary arteritis score > 0, CA(-): coronary arteritis score = 0, SG: saline including 0.1% glucose. Data are expressed as
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that has been shown to be effective in treating some
children unresponsive to IVIg therapy also dramatically
suppresses the development of vasculitis in this mouse
model of KD (manuscript in preparation). Thus this
mouse model appears to be valuable for evaluation of
alternative therapies for KD arteritis.
Reduction of inflammatory cytokines and chemokines by
treatment with MZR
Some cytokines and chemokines such as IL-1b, IL-2, sIL-
2R, IL-4, IL-6, IL-8, IL-10, IL-12, IL-15, RANTES, MCP-1,
M-CSF, G-CSF, and MIPs are elevated in the blood of
patients with acute-phase KD. Some elevated cytokines
and chemokines are decreased by IVIg treatment in the
acute phase, when it is effective [35]. On the other hand,
IL-6, TNF-a, IL-4, and IL-12 were increased in the plasma
of the KD mouse model induced with C. albicans-derived
substances (CADS) [36]. Moreover, IL-6 and IFN-g in
splenocytes administered CAWS in C57BL/6 mice were
elevated [37]. With IVIg treatment of KD model mice
induced with CAWS, elevated proinflammatory cytokines
IL-1a,T N F - a, IL-10, IL-13, and MCP-1 were decreased in
our data. Furthermore, chemokines IL-1a,T N F - a,K C ,
GM-CSF, IL-13, and MIP-1a in plasma of autopsied mice
were decreased in the MZR treatment group in the pre-
sent study. The results with MZR treatement show similar
effects as well as IgG treatment for KD model mice. How-
ever, supression levels of IL-1a, TNF-a, IL-10, IL-13, and
MIP-1a in the recovery group from the coronary arteritis
(CA(-)) in the MZR group differed from those in the IgG
group. Levels in the recovery group (CA(-)) after MZR
treatment were not suppressed, whereas those in the CA
(-) group after IgG treatment were suppressed in the pre-
sent study, which suggests that MZR may have a stronger
effect than a high dose of IgG (400 mg/kg/day for 5 days).
Because these cytokines/chemokines decrease slightly after
MZR treatment, they may have a role in the development
of coronary arteritis in the KD model.
Effective treatment with MZR of model mice for KD
induced by CAWS
In the present study, MZR treatment of the KD model
mice significantly suppressed the development of coron-
ary arteritis associated with significant suppression of
levels of proinflamatory cytokines and chemokines in
plasma. These results suggest association of the suppres-
sion of lymphocyte proliferation with MZR [38]. The
mode of action of MZR is that it mainly blocks immu-
nosuppression related to lymphocyte proliferation
through inhibition of purine synthesis [32,39,40]. In the
present study, the incidence of panarteritis decreased to
half, and both the scope and severity of inflammation
were limited after administration of MZR. In addition to
the lymphocyte action, these observations suggest that
MZR may act on functions of monocytes/macrophages
and neutrophils, which are mainly involved in the devel-
opment of inflammation, resulting in the possible sup-
pression of coronary arteritis through suppression of
proinflammatory cytokines and chemokines released
from these cells. Indeed, recently, MZR acted to inhibit
functions of lymphocytes as well as those of macro-
phages, such as migration and production of Nitrous
Oxide Systems (NOS), IL-1b,a n dT N F - a in a dose-
dependent manner [41,42]. Furthermore, in the mixed
lymphocyte reaction method (MLR) of human periph-
eral blood mononuclear cells, the IC50 is 1 μg/ml [43].
In addition, MLR of T-cells in human peripheral blood,
which are stimulated with anti-CD3 monoclonal anti-
body, shows an IC50 of less than 1 μg/ml for MZR and
also phorbol myristate stimulation less than 5 μg/ml
[44]. In addition, MZR also inhibits activation of M1
macrophages [42], which are classified as inflammatory,
showing tissue injury and activation with IFN-g.I nt h e
present study, suppression profiles of proinflammatory
cytokines and chemokines by MZR treatment of KD
model mice seem to be associated in the literature with
those in the M1 macrophage. Therefore, the effect of
MZR on KD model mice may be to inhibit the prolifera-
tion of lymphocytes and activation of macrophages and
neutrophils associated with elevation of proinflamatory
cytokines and chemokines.
Based on these observations, suppression of develop-
ment of coronary arteritis associated with suppression
of proinflammatory cytokines and chemokines by
MZR treatment for the KD model mice suggests that
MZR may be useful for patients with KD in the acute
phase. MZR has been used as therapy for kidney
transplantation, lupus nephritis, nephrotic syndrome,
and rheumatoid disease with few side effects [24].
Furthermore, MZR has been used as maintenance
treatment for ANCA-associated vasculitis, frequently
relapsing nephrotic syndrome, and purpura nephritis
[29,30]. Clinical use will be recommended for immune
dysfunctions when the safety of long-time use
becomes known. Therefore, MZR is a possible therapy
for patients with KD who are nonresponsive to IVIg.
Conclusions
MZR treatment suppressed not only the incidence,
range, and degree of vasculitis, but also inflammatory
cytokines and chemokines in the plasma of the KD vas-
culitis model mice. It appears likely that MZR may
prove to be a useful for alternative treatment for KD.
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